Back to Search
Start Over
Economic assessment on the management of chronic lymphocytic leukaemia.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2005 Jun; Vol. 6 (7), pp. 1179-89. - Publication Year :
- 2005
-
Abstract
- In the last decade, several new promising treatments for chronic lymphocytic leukaemia (CLL) have been developed. Healthcare costs are increasing and new treatments tend to be very expensive; therefore, information about the cost effectiveness in treatments for CLL is urgently needed. The authors performed a literature review on the currently available economic evaluations on CLL treatments. A total of 65 articles were found, of which 11 could be included. These articles were evaluated on the basis of six methodological requirements for economic evaluations, enabling readers to judge the value of the studies. Only a small amount of information was available on the costs of CLL treatments. Future economic evaluations should be performed according to the methodological requirements for these studies, which should also be properly documented.
- Subjects :
- Algorithms
Antibodies, Monoclonal economics
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Chlorambucil economics
Chlorambucil therapeutic use
Cost-Benefit Analysis
Hospital Costs
Humans
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell radiotherapy
Lymphoma, Non-Hodgkin economics
Lymphoma, Non-Hodgkin therapy
Randomized Controlled Trials as Topic
Vidarabine analogs & derivatives
Vidarabine economics
Vidarabine therapeutic use
Antineoplastic Agents economics
Health Care Costs
Leukemia, Lymphocytic, Chronic, B-Cell economics
Stem Cell Transplantation economics
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 6
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 15957971
- Full Text :
- https://doi.org/10.1517/14656566.6.7.1179